Jnana Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $107M
Overview
A biotech using its RAPID platform to develop small molecule drugs targeting metabolite transporters for immunology and metabolic diseases.
ImmunologyMetabolic
Technology Platform
The RAPID platform is an integrated drug discovery engine designed to identify small molecule modulators of solute carrier (SLC) transporters, a historically challenging target class.
Funding History
1Total raised:$107M
Series B$107M
Opportunities
Validating SLC transporters as a druggable target class could unlock a vast pipeline of first-in-class medicines across immunology and metabolism.
Risk Factors
High biological risk as the SLC target class is largely unproven clinically, and lead candidate JNT-517 must demonstrate safety and efficacy in ongoing trials.
Competitive Landscape
Faces competition from other PKU therapies like enzyme replacement (Palynziq) and gene therapy approaches, but its novel SLC mechanism is distinct; platform competition is limited but includes early-stage biotechs like SLC Therapeutics.